Appendix Table C15. KQ1 Outcome I. Hematologic response subgroup analysis: Darbepoetin versus epoetin

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Study** | **Subgroups prospectively** **stratified for**  | **Darb n/N (%)** | **Epo n/N (%)** | **p-value** |
| **Schwartzberg 2004**      | Overall population  | 108/157 (69%) | 112/155 (72%) | NR |
| Breast cancer | 63/72 (88%) | 56/69 (81%) | NR |
| Lung cancer | 25/51 (49%) | 30/51 (59%) | NR |
| Gynecological cancers | 21/34 (62%) | 26/35 (74%) | NR |
| Hb < 10.5 | 21/38 (55%) | 18/38 (47%) | NR |
| Hb > 10.5 | 88/119 (74%) | 94/117 (80%) | NR |